Table 1.
Patient Demographics and Baseline Characteristics
| Item | n (%) |
|---|---|
| Safety analysis population | 1049 |
| Sex | |
| Male | 413 (39.4) |
| Female | 636 (60.6) |
| Age (mean ± SD, yr) | 70.4 ± 17.2 |
| < 65 | 286 (27.3) |
| ≥ 65 | 763 (72.7) |
| < 75 | 518 (49.4) |
| ≥ 75 | 531 (50.6) |
| Duration of chronic constipation (yr) | |
| < 5 | 380 (36.2) |
| ≥ 5 | 486 (46.3) |
| Unknown | 183 (17.4) |
| IBS-C | |
| No | 936 (89.2) |
| Yes | 113 (10.8) |
| Combined disease | |
| No | 285 (27.2) |
| Yes | 764 (72.8) |
| Hypertension | 317 (41.5) |
| Dyslipidemia | 208 (27.2) |
| Diabetes mellitus | 153 (20.0) |
| Gastroesophageal reflux disease | 148 (19.4) |
| Cardiovascular disease | 101 (13.2) |
| Respiratory disease | 67 (8.8) |
| Kidney disease | 60 (7.9) |
| Depression | 40 (5.2) |
| Liver disease | 27 (3.5) |
| Parkinson's disease | 21 (2.7) |
| Biliary disease | 13 (1.7) |
| Other diseases | 454 (59.4) |
| Prior OTC laxative | |
| No | 877 (83.6) |
| Yes | 93 (8.9) |
| Unknown | 79 (7.5) |
| Prior prescribed laxative | |
| No | 350 (33.4) |
| Yes | 699 (66.6) |
| Concomitant drugs for constipation | |
| No | 635 (60.5) |
| Yes | 414 (39.5) |
IBS-C, irritable bowel syndrome with constipation; OTC, over-the-counter.
Laxatives used within 1 month prior to treatment with elobixibat were recorded.